UCK2 and hepatocellular carcinoma: In fact, we have demonstrated that concurrent pharmacologic targeting the metabolic and non-metabolic features of UCK2 by ECyd and Erlotinib, respectively, could synergistically inhibit HCC growth and metastasis (27).